Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 12/20 | 0.67 |
| ▸ | EZH1 | Q92800 | 11/20 | 0.67 |
| ▸ | EED | O75530 | 2/20 | 0.67 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.67 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.67 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.67 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.67 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.67 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16115719 | 0.90 | EZH2 (0.67) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL16115816 | 0.89 | EZH2 (0.70) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL16115250 | 0.85 | EZH1 (0.67) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL2592678 | 0.84 | EZH2 (0.81) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL20992055 | 0.84 | EZH2 (0.81) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL30956686 | 0.84 | EZH2 (0.81) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL14917586 | 0.83 | EZH2 (0.66) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL23863738 | 0.83 | EZH2 (0.72) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL2594803 | 0.82 | EZH1 (0.82) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734425 | 0.82 | EZH2 (0.70) | EZH2EZH1EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014155301-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS INHIBITORS OF EZH2 | Piramal Enterprises Limited (IN) | 2014-10-02 | — | — | WO | disclosed |